Here Are the 3 Most Important Numbers in Moderna's Earnings Report
Moderna's (NASDAQ: MRNA) transformation from a clinical-stage biotech company to a commercial-stage one has been rapid -- and impressive. Only a year ago, Moderna didn't even have products on the market. And now, in its first full quarter of sales, the company's coronavirus vaccine generated $1.7 billion. And resulted in profitability -- $1.2 billion to be exact.
Those first-quarter numbers show Moderna is off to a solid start as a commercial-stage company. But three other numbers in the report are even more important. Why? Because they set the tone for what's to come.
Image source: Getty Images.
Source Fool.com
